首页> 美国卫生研究院文献>other >In vivo acute toxicity evaluation and in vitro molecular mechanism study of antiproliferative activity of a novel indole Schiff base β-diiminato manganeseIII complex in hormone-dependent and triple negative breast cancer cells
【2h】

In vivo acute toxicity evaluation and in vitro molecular mechanism study of antiproliferative activity of a novel indole Schiff base β-diiminato manganeseIII complex in hormone-dependent and triple negative breast cancer cells

机译:新型吲哚席夫碱β-二亚氨基锰III配合物在激素依赖性和三阴性乳腺癌细胞中的体内急性毒性评价和体外分子机制研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Breast cancer is the most frequently diagnosed cancer among women worldwide. Recently, increasing attention has been paid to the anticancer effects of transition metal complexes of indole Schiff bases. β-diiminato ManganeseIII complex has shown promising cell cycle arrest and apoptosis induction against MCF-7 and MDA-MB-231 breast cancer cells. In this study, time- and dose- dependent inhibitory activity were evaluated using MTT assay after 48 h and 72 h exposure time. In addition, median effect analysis was conducted according to Chou–Talalay method to investigate whether MnIII complex has synergistic effect in combination with chemotherapeutic drugs on inhibiting breast cancer cell growth. The molecular mechanisms underlying its potent antiproliferative effect was determined through bioluminescent caspase-3/7, -8 and -9 activity assays and quantitative expression analysis of cell cycle- and apoptosis-related genes. Furthermore, safety evaluation of MnIII complex was assessed through the acute oral toxicity test in in vivo model. The MTT assay results revealed that it potently reduced the viability of MCF-7 (IC50 of 0.63 ± 0.07 µg/mL for 48 h and 0.39 ± 0.08 µg/mL for 72 h) and MDA-MB-231 (1.17 ± 0.06 µg/mL for 48 h, 1.03 ± 0.15 µg/mL for 72 h) cells in dose- and time-dependent manner. Combination treatment also enhanced the cytotoxic effects of doxorubicin but not tamoxifen on inhibiting breast cancer cell growth. The involvement of intrinsic and extrinsic pathway in apoptosis induction was exhibited through the increased activity of caspase-9 and caspase-8, respectively, leading to enhanced downstream executioner caspase-3/7 activity in treated MCF-7 and MDA-MB-231 cells. In addition, gene expression analysis revealed that MnIII complex exerts its antiproliferative effect via up-and down-regulation of p21 and cyclin D1, respectively, along with increased expression of Bax/Bcl-2 ratio, TNF-α, initiator caspase-8 and -10 and effector caspase-3 in MCF-7 and MDA-MB-231 cells. However, the results did not show increased caspase-8 activity in treated MCF-7 cells. Furthermore, in vivo acute oral toxicity test revealed no signs of toxicity and mortality in treated animal models compared to the control group. Collectively, the promising inhibitory effect and molecular and mechanistic evidence of antiproliferative activity of MnIII complex and its safety characterization have demonstrated that it may have therapeutic value in breast cancer treatment worthy of further investigation and development.
机译:乳腺癌是全世界女性中最常被诊断出的癌症。最近,对吲哚席夫碱的过渡金属配合物的抗癌作用越来越关注。 β-二亚氨基锰 III 复合物对MCF-7和MDA-MB-231乳腺癌细胞具有良好的细胞周期阻滞和凋亡诱导作用。在这项研究中,暴露时间分别为48小时和72小时后,采用MTT法评估了时间和剂量依赖性抑制活性。此外,根据Chou–Talalay方法进行了中值效应分析,以研究Mn III 复合物与化学治疗药物联合抑制乳腺癌细胞生长是否具有协同作用。通过生物发光caspase-3 / 7,-8和-9活性测定以及细胞周期和凋亡相关基因的定量表达分析,确定了其潜在的抗增殖作用的分子机制。此外,通过体内模型急性口服毒性试验评估了Mn III 复合物的安全性。 MTT分析结果表明,它有效降低了MCF-7的活力(IC50在48小时内为0.63±0.07μg/ mL,在72小时内为0.39±0.08μg/ mL)和MDA-MB-231(1.17±0.06μg/ mL) mL剂量依赖性和时间依赖性48小时,1.03±0.15 µg / mL 72 h)细胞。联合治疗还增强了阿霉素而不是他莫昔芬对抑制乳腺癌细胞生长的细胞毒性作用。通过增加caspase-9和caspase-8的活性来显示内在途径和外在途径参与凋亡诱导,从而导致在处理过的MCF-7和MDA-MB-231细胞中下游执行者caspase-3 / 7活性增强。 。此外,基因表达分析表明,Mn III 复合物通过分别上调和下调p21和cyclin D1以及增加Bax / Bcl-2比,TNF的表达发挥其抗增殖作用。 -α,MCF-7和MDA-MB-231细胞中的启动子caspase-8和-10以及效应子caspase-3。但是,结果未显示在处理过的MCF-7细胞中caspase-8活性增加。此外,与对照组相比,体内急性口服毒性试验显示在治疗的动物模型中没有毒性和死亡率的迹象。综上所述,Mn III 复合物的抗增殖活性及其分子生物学机制及其安全性表征均具有广阔的发展前景,其在乳腺癌的治疗中具有治疗价值,值得进一步研究和开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号